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Central venous port system associated thromboses:
outcome in 3498 implantations and literature review
Thrombosehäufigkeit bei zentralvenösen Portsystemen:
Erfahrungsbericht über 3498 Portimplantationen im Literaturvergleich
Abstract
Methods: From 1 July 1995 to 31 June 2006 we implanted 3498 intra-
venous port systems. In nearly all cases the indication was vascular
access for chemotherapy.
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Results: We registered 199 complications (5.7%), mostly infections
(n=85 i.e. 2.4%) and thromboses (n=63 i.e. 1.8%). 1 Klinik für Gefäß- und Thorax-
chirurgie, Klinikum Ernst von Conclusions: Permanent central venous catheters have become
standard in the management of patients with malignancies. Because BergmanngGmbH,Potsdam,
Deutschland oftheimprovementofmaterialanddesignduringthepasttwentyyears
technical complications have been reduced significantly. The most fre-
quent occurring medical complications are infection and thromboses.
In order to further minimize these disadvantages we developed a “best
practices“standardforportimplantationcombiningowndatawithrecent
studies.
Keywords: central venous port systems, associated thromboses
Zusammenfassung
Methoden: Vom 01.07.1995 bis 31.06.2006 haben wir 3498 zentral-
venösePortsystemeimplantiert.Inüber99%derFällewardieIndikation
ein dauerhafter, verlässlicher Zugang zur Chemotherapie.
Ergebnisse:Wirsahen199Komplikationen(5,7%),davon85Infektionen
(2,4%) und 63 Thrombosen (1,8%).
Schlussfolgerung:DieImplantationzentralvenöserPortkatheteristzum
StandardbeimManagementvonPatientengeworden,dieeinerChemo-
therapie bedürfen. Aufgrund der Weiterentwicklung von Material und
Design während der letzten zwanzig Jahre konnte die Rate an techni-
schenKomplikationensignifikantgesenktwerden.Zudenamhäufigsten
auftretenden medizinischen Komplikationen zählen Infektionen und
Thrombosen.UmdieseNachteileweiterzureduzieren,habenwireinen
„Best Practices“-Standard aus eigenen Daten und aktuellen Studien
entwickelt.
Schlüsselwörter: zentralvenöse Portsysteme, Thrombosehäufigkeit
Introduction
Implanted central venous port catheter systems (CVC) is
today an important component in the management of
oncology patients. The system provides a safe vascular
access with a low complication rate whereas infections
as well as catheter associated thromboses are the most
common observed findings [36]. However, thrombosis is
apotentialcomplicationwhichcancauseseriousmorbid-
ity. In the present study we assembled and analysed the
incidencesofcatheter-relatedvenousthrombosesamong
our patients. In order to further minimize the already low
complication rate we summarized our experience com-
pared to recent studies with the aim to develop a “best
practices” standard for port implantation.
Material and methods
In the period between 1 July 1995 and 31 June 2006 a
total of 3498 patients at the Clinic for Vascular and
Thoracic Surgery at the Klinikum Ernst von Bergmann
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Review Article OPEN ACCESSgGmbH Potsdam underwent implantation of a CVC in an
outpatient as well as inpatient setting. Out of these pa-
tients, 1889 were female and 1609 male, with an aver-
age age of 57 years (16-89 years) (Table 1). The main
indication for port implantation was in 99 per cent of
cases intravenous chemotherapy for patients with malig-
nant tumours. All patients were observed and followed
postoperativelyaswellasduringthecourseoftheirinpa-
tient stay at the clinic. Outpatients were followed at the
oncology day clinic.
Table 1: Gender distribution, age and indication
Three port systems manufactured by the companies
Braun(Celsite
®siliconcatheter:6.5F/8.5F),Arrow(A-port
®
silicon catheter: 8.4F/9.6F) and Vygon (Vygon
® silicon
catheter: 6.6F/9.6F) were used. The preferred site of
implantationwastherightcephalicveinaccessedthrough
a surgical cutdown approach under local anaesthesia.
The exact catheter tip position was checked intraopera-
tively under radiographic screening. If the implantation
was impossible or not indicated on the right hand side
due to lung or breast cancer the left cephalic vein was
used. In case of an inapt cephalic vein we punctured the
subclavian vein from the incision using Seldinger tech-
nique (n=106) or cutdown (n=196) during the same
session. In the event of an impaired central venous
drainage we selected in one case to implant via the right
femoral vein and in another case we used the left basilic
vein.Innocaseaportcatheterinsertionusingthejugular
vein was performed.
Administering contrast injection containing iodine was
unnecessarygivingtheproblem-freevenousportimplant-
ation and the intraoperative monitoring of the function
of the port. At the end of the operation the CVC was
flushed and locked with heparinized saline (200 IE
UFH/ml). A general thromboprophylaxis was not given. A
chest x-ray in exspiration was routinely performed at the
end of the procedure.
Theportswereavailableforuseimmediatelyafterimplant-
ation. Care and maintenance of the device were carried
out according to the recommendations outlined in Table
2 by an experienced nursing staff.
Table 2: Care guidelines during port usage
Results
Between July 1995 and June 2006, 3498 venous port
implantations were carried out on adult patients with
malignant disease (Figure 1, Table 1). A total of 199
complications occurred listed in Table 3. The most fre-
quentlyencounteredcomplicationswereinfections(n=85)
andthromboses(n=63).Wedeterminedthromboembolic
complications, all clinically relevant occlusions of central
veins as well as catheter-related thrombosis demon-
strated by color Duplex ultrasonography. The clinical
symptomes spanned the spectrum from local problems
like arm swelling, pain, malfunction of the port systems
to the appearance of collateral circulation and dyspnea.
A fatal pulmonary embolism or postphlebitic syndrome
did not occur.
Table 3: Complications (n=199)
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Discussion
Infections and thromboses were the most often seen
complicationsfollowingaportimplantation.Acorrelation
of the two has been suspected by many authors [20].
Thereforewehaveretrospectivelycomparedourincidence
of thrombosis in CVC with recent studies. Only studies
withasufficientpatientpopulation(n>200)summarized
in Table 4 qualified for our analysis.
Wefoundaconsiderablyhighvariationoftheoccurrence
of thrombembolic complications in port systems (range
between 1.4 per cent and 9.2 per cent) [12], [34]. This
prompted us to work out possible risk factors in port-as-
sociated thrombosis listed in Table 5 as well as their
prevention. Implantation techniques, material, time of
port insertion, experience and postoperative handling
can be directly influenced by the implantation team, i.e.
prevention is possible. Nontheless, there are important
risk factors outside of the team’s control: type of malig-
nancies, chemotherapy agents, and general risk factors
(e.g. obesity, smoking, immobility, age).
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Figure 1: Port implantations 07/95-06/06 (n=3498)Table 5: Thrombosis-related risks factors
1. Risk factor implantation techniques
Venousthromboemboliccomplicationsoccurmoreoften
in peripherally implanted venous ports than in venous
chest ports. Numerous studies have shown that thoracic
wall implanted ports are less prone to thrombotic epis-
odes than armports. The stabile position, the shorter
feedingpath,lessforeignmaterialandamorefavourable
implantation procedure combined with a large lumen
access vessel will reduce the incidence of thrombosis
[1], [6], [7], [11], [15], [17], [19], [20], [31], [33], [36],
[37].
Therewasfurtherevidencethatendothelialdamagedue
to the traumatization of the Seldinger puncture wire with
the vessel wall enhances the risk for thrombosis [18],
[19],[20],[24],[26],[31].Thissupportstheopensurgical
port implantation procedure in contrast to the subcu-
taneous vein puncture technique [15], [36]. Hall et al.
[8]demonstratedthatcatheterocclusionismorecommon
following inexact location of the tip of the catheter in the
superior vena cava. He suspected as cause an unfavour-
ablerateofflowinadditiontothedangerofbloodflushing
the catheter. Thus, the exact catheter tip position should
becheckedintraoperativelyunderradiographicscreening.
2. Risk factor material
Some current data suggest that polyurethane catheter
have a lower risk for thrombosis than silicon catheter.
Polyurethane catheter have a smooth surface which di-
minishes the adhesion of thrombocytes [7], [22]. Other
studies have shown no significant difference in respect
to complication rates [6], [15]. Due to lack of significant
data, for the authors this question still remains open.
3. Risk factor experience of the
implantation team and postoperative
care
Itisindisputablethataversedimplantationteamcontrib-
utestothereductionoftheriskprofile.Expedientvenous
cutdown and less trauma to the vein will result in a signi-
ficant long term reduction of the risks of thrombosis.
Furthermore, the safe handling of the CVC is greatly en-
hanced by utilization of a limited number of established
cathetersystems.Experiencedandwell-trainedmainten-
ance following strict adherence to the application of care
instructions (Table 2) will likewise reduce the rate of
complications as many studies have shown [5], [6], [15],
[16], [28], [29], [31].
4. Risk factor time of port implantation
Theportimplantationshouldbedoneasearlyaspossible.
At best it should be carried out at the beginning of
chemotherapy.Multiplevenouspuncturesharmtheveins.
Phlebothrombosis as well as already elapsed thrombotic
episodes will increase the risk for thrombosis [35].
5. Risk factor tumour disease
Patients with a malignant primary disease are for a
plethora of reasons subject to a higher risk of venous
thromboembolism.Manyfactorsarethoughttocontribute
to the risk of thrombosis. These include the continuous
releaseofbloodcoagulationtissuefactor,changesinthe
composition of the haemostatic parameters (elevated
fibrinogen, Factor VIII, and the PAI-Level) and damage to
the endothelium [10]. Broad-based investigations
demonstrated that the increased risk for venous throm-
boembolism is associated with different kinds of malig-
nant diseases.
Kakkar et al. [13] showed in a study based on a survey
of 3891clinicians worldwide who responded to a ques-
tionnaire that tumours of the central nervous system as
well as the gastrointestinal system especially the pan-
creas carry a higher risk for thrombosis compared to
other primary malignancies.
Levitan et al. [21] analysed a patient population of 1.2
million with malignant disease and discovered that the
highest risk for thrombosis is found in patients with
uterine, ovarian, brain and pancreatic malignancies as
well as leukaemia.
6. Risk factor chemotherapy
Thevariedtumourgenicityofdifferentchemotherapeutic
agents have already been investigated. Nanninga [27]
andPritchard[30]foundasignificantincreaseintherisk
for thrombosis in patients treated with CMF-chemother-
apy.Doxorubicinlikewiseelevatestheriskofthromboem-
bolism [23].
7. General risk factors
Age above 60 years, obesity, varicose, smoking, surgical
procedures and immobility are all known risk factors in
the occurrence of thromboembolic complications.
8. Thromboprophylaxis
Because of the potentially dangerous effects of port-as-
sociated thrombosis many authors discussed preventive
approaches utilising anticoagulants while avoiding to in-
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tients.
Various studies analysed whether a low-dose of a cu-
marin-derivative or a low molecular weight heparin
(LMWH) provides enough protection against thrombosis.
The results as shown in Table 6 are controversial. Cur-
rently, a consensus exists to not recommend a general
thromboprophylaxis after CVC implantation [10], [18],
[38]. Further prospective investigations must be carried
out to clarify this issue.
Table 6: Thromboprophylaxis
Conclusions
Subcutaneousvenousportdevicesprovideaconsiderable
facility in the care of oncology patients. The rate of com-
plications must be acceptable even for patients in a poor
state of bodily health. Through the improvement of ma-
terial and design of the port catheter in the last twenty
years a significant reduction of technical complications
couldbeachieved.Thetaskremainstodiminishthemost
oftenoccurringmedicalcomplications.Withtheinclusion
ofliteraturereviewsweworkedoutanapproachtoreduce
suchcomplicationseventhoughthemultifactorialgenesis
of the venous thromboembolism in oncology patients
exacerbated the effort. Regardless factors capable of
being influenced to reduce the incidence of catheter-as-
sociated thrombosis were worked on with the aim to de-
velop a “best practices” standard for port implantation.
The preferred vascular access for port catheter implant-
ationshouldbeviatherightcephalicveinfollowedbythe
right subclavian vein. The reasons are a sufficient large
lumen of the venous access, the shortest and most fa-
vourable course of implantation and the most stabile
position in the area of the thoracic wall. This will contrib-
ute to a considerable reduction in the risk of thrombosis
compared to armports.
Furthermore, we recommend to use an open surgical
approach in CVC implantation carried out by well-trained
staff. This will result in shorter operating time and avoids
damage to the endothelium through the manipulation
and perforation of the wire as well as better hemostasis
andavoidanceofhematomawithaccompaniedinfections.
A more interdisciplinary teamwork between vascular
surgeons and oncologists as well as regular training of
doctors,nursingstaffandpatientsinthehandlingofport
systemsareanotherimportantelementinminimizingthe
complication rate.
The individual specification of a thromboprophylaxis ac-
cording to the risk profile could likewise reduce the incid-
enceofcatheter-associatedthrombosis.Forthatweneed
more standard prospective studies which build on the
already existing management recommendations in the
treatment of catheter-associated complications.
Notes
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